Company: DMAC
Filing Date: 2025-03-28
Form Type: DEF 14A
Source: 0001437749-25-009696
Chunk: 56

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-03-28
Form: DEF 14A
Chunk 56
---
:|:----|:-------|--------:|:----|:---------|:--|:----|:----------|--------:|:----|:----------|--------:|:----|:----------|-------:|:----|:------|----------:|
| Rick Pauls                            |     | 2024 |     | $      | 593,250 |     | $        | — |     | $         | 633,510 |     | $         | 306,975 |     | $         | 17,250 |     | $     | 1,550,985 |
| President and Chief Executive Officer |     | 2023 |     |        | 562,000 |     |          | — |     |           | 396,553 |     |           | 239,958 |     |           | 16,650 |     |       | 1,215,161 |
| Lorianne Masuoka, M.D.(5)             |     | 2024 |     |        | 403,277 |     |          | — |     |           | 637,260 |     |           | 116,667 |     |           | 17,106 |     |       | 1,174,310 |
| Chief Medical Officer                 |     |      |     |        |         |     |          |   |     |           |         |     |           |         |     |           |        |     |       |           |
| Scott Kellen                          |     | 2024 |     |        | 374,250 |     |          | — |     |           | 274,521 |     |           | 147,934 |     |           | 17,250 |     |       |   813,955 |
| Chief Financial Officer and Secretary |     | 2023 |     |        | 352,750 |     |          | — |     |           | 146,790 |     |           | 116,025 |     |           | 16,650 |     |       |   632,215 |

| (1) | We generally do not pay discretionary bonuses. Our annual cash bonuses which are typically based on performance and measured against pre-established performance goals are reported in the “Non-Equity Incentive Plan Compensation” column. |

<div align='center'>47</div>

| (2) | Amounts reflect the full grant-date fair